A litany of failures spanning inadequate personnel, manufacturing, cleaning and other lapses have resulted in the FDA serving a Form 483 to Advanced Cosmetic Research Laboratories (ACRL) following the agency’s July 2023 inspection of the Chatsworth, Calif., facility.
Source: Drug Industry Daily